Drug Profile
Research programme: peptide-based viral entry inhibitors - Autoimmune/Tulane University
Alternative Names: CSW-1Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Autoimmune Technologies; Tulane University School of Medicine
- Class Monoclonal antibodies; Peptides
- Mechanism of Action Viral envelope protein inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dengue; Ebola virus infections; Hepatitis C; HIV-1 infections; Lassa fever; Measles; Middle East respiratory syndrome coronavirus; Respiratory syncytial virus infections; Severe acute respiratory syndrome; West Nile virus infections
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Dengue in USA (Parenteral)
- 28 Jul 2018 No recent reports of development identified for research development in Ebola-virus-infections in USA (Parenteral)
- 28 Jul 2018 No recent reports of development identified for research development in Hepatitis-C in USA (Parenteral)